While OpenAI inks Stargate, Anthropic touts Claude Cowork, and Google opens I/O, Cohere has quietly acquired Reliant AI, a Canadian-German biopharma AI company. No long Twitter posts, no launch video, no 'making the world a better place.'
Cohere's Chief AI Officer Joelle Pineau set the tone: 'Cohere is a very low drama company.'
In plain terms: while others talk AGI, superintelligence, and white-collar replacement within six months, Cohere's slogan is simple: ROI over AGI.
What is Reliant AI?
Headquartered in Montreal and Berlin, Reliant AI helps pharmaceutical companies process and understand massive datasets, including:
- Clinical trial data
- Molecular structure screening
- Drug interaction modeling
- Regulatory document parsing
This is Cohere's second acquisition in six months. The previous one was Germany's Aleph Alpha, one of Europe's most prominent 'sovereign AI' projects, with a combined valuation of roughly $20 billion. With this deal, Cohere expands from enterprise LLMs into the pharma vertical.
Canada-Germany dual HQ, backed by governments
Cohere now has a unique structure: Toronto + Berlin dual headquarters, with support from both the Canadian and German governments. Offices in San Francisco, New York, London, and Paris. The company's mission is clear: provide an alternative to OpenAI and Anthropic for national-level clients in Europe and Asia.
'Sovereign AI' has been overused in recent years, but Cohere treats it as a real business. The Aleph Alpha deal effectively took over Germany's national AI project. The Reliant AI acquisition adds specialized data processing capabilities for pharma—a sector where data is heavily regulated in the EU and Canada, making data export a compliance minefield.
The subtext of 'low drama'
Pineau stated plainly in public interviews that she has friends at OpenAI and Anthropic, but Cohere won't follow them: 'People are worried whether that's going to impact their jobs, their ability to have a livelihood.' She avoids discussing 'AGI risk' and instead focuses on worker jobs, data privacy, and infrastructure security.
This positioning is counterintuitive in 2026—Silicon Valley's mainstream narrative is bigger, faster, more aggressive. Cohere goes the opposite: slower, steadier, more focused on clients.
Is this move worth it?
Placing Cohere in the broader AI competition:
- Top-tier models: Not necessarily the strongest compared to OpenAI, Anthropic, Google
- Enterprise deployment: Not the widest compared to Anthropic, Microsoft
- Sovereign AI: Nearly a monopoly—Europe, Canada, parts of Southeast Asia prefer Cohere
With Reliant AI, Cohere gains a vertical story in pharma to sell to clients. This 'small and specialized' acquisition is far more pragmatic than spending $20 billion on a cloud computing contract. Whether this path can ultimately outrun Silicon Valley's 'AGI or Die' camp will likely be answered by IPO filings. Cohere itself has already hinted at going public earlier this year.
Sources: CocoLoop, Canadian AI firm Cohere expands further with biomedical acquisition (Canadian Affairs); Canada's Cohere embraces 'low drama' amid AI giant tumult (Tech Xplore)